Terms: = Kidney tumors AND PIK3CA, MGC142161, 5290, ENSG00000121879, P42336, MGC142163, p110-alpha, PI3K AND Treatment
222 results:
1. VHL governs m6A modification and PIK3R3 mRNA stability in clear cell renal cell carcinomas.
Lee H; Zhuang L; Gan B
J Clin Invest; 2024 Apr; 134(8):. PubMed ID: 38618953
[TBL] [Abstract] [Full Text] [Related]
2.
Miao X; Jiang P; Zhang X; Li X; Wu Z; Jiang Y; Liu H; Xie W; Li X; Shi B; Cai J; Gong W
Microbiol Spectr; 2024 May; 12(5):e0183923. PubMed ID: 38564670
[TBL] [Abstract] [Full Text] [Related]
3. Designing a predictive Framework: Immune-Related Gene-Based nomogram and prognostic model for kidney renal papillary cell carcinoma.
Lim A; Edderkaoui M; Zhang Y; Wang Q; Wang R; Pandol SJ; Ou Y
Int Immunopharmacol; 2024 Apr; 131():111878. PubMed ID: 38493693
[TBL] [Abstract] [Full Text] [Related]
4. Renal Cell Cancer - Insights in Drug Resistance Mechanisms.
Aweys H; Lewis D; Sheriff M; Rabbani RD; Lapitan P; Sanchez E; Papadopoulos V; Ghose A; Boussios S
Anticancer Res; 2023 Nov; 43(11):4781-4792. PubMed ID: 37909991
[TBL] [Abstract] [Full Text] [Related]
5. Comprehensive exploration of Biochanin A as an oncotherapeutics potential in the treatment of multivarious cancers with molecular insights.
Sohel M
Phytother Res; 2024 Feb; 38(2):489-506. PubMed ID: 37905329
[TBL] [Abstract] [Full Text] [Related]
6. Exploring the material basis and mechanism of action of clinacanthus nutans in treating renal cell carcinoma based on metabolomics and network pharmacology.
Ye Z; Fang Z; Li D; Lin X; Huang S
Medicine (Baltimore); 2023 Oct; 102(42):e35675. PubMed ID: 37861516
[TBL] [Abstract] [Full Text] [Related]
7. Modified Bushen Yiqi formula enhances antitumor immunity by reducing the chemotactic recruitment of M2-TAMs and PMN-MDSCs in Lewis lung cancer-bearing mice.
Kong Q; Zhu H; Gong W; Deng X; Liu B; Dong J
J Ethnopharmacol; 2024 Jan; 319(Pt 1):117183. PubMed ID: 37739106
[TBL] [Abstract] [Full Text] [Related]
8. CUDC-907, a dual pi3k/histone deacetylase inhibitor, increases meta-iodobenzylguanidine uptake (
Grand-Guillaume J; Mansi R; Gaonkar RH; Zanger S; Fani M; Eugster PJ; Beck Popovic M; Grouzmann E; Abid K
J Transl Med; 2023 Sep; 21(1):604. PubMed ID: 37679770
[TBL] [Abstract] [Full Text] [Related]
9. A novel drug specific mRNA biomarker predictor for selection of patients responding to dovitinib treatment of advanced renal cell carcinoma and other solid tumors.
Knudsen S; Hansen A; Foegh M; Petersen S; Mekonnen H; Jia L; Shah P; Martin V; Frykman G; Pili R
PLoS One; 2023; 18(8):e0290681. PubMed ID: 37647320
[TBL] [Abstract] [Full Text] [Related]
10. The multi-omics analyses of acsl1 reveal its translational significance as a tumor microenvironmental and prognostic biomarker in clear cell renal cell carcinoma.
Yang Y; Liang J; Zhao J; Wang X; Feng D; Xu H; Shen Y; Zhang Y; Dai J; Wang Z; Wei Q; Liu Z
Diagn Pathol; 2023 Aug; 18(1):96. PubMed ID: 37608295
[TBL] [Abstract] [Full Text] [Related]
11. pi3k/Akt signaling in urological cancers: Tumorigenesis function, therapeutic potential, and therapy response regulation.
Rezaei S; Nikpanjeh N; Rezaee A; Gholami S; Hashemipour R; Biavarz N; Yousefi F; Tashakori A; Salmani F; Rajabi R; Khorrami R; Nabavi N; Ren J; Salimimoghadam S; Rashidi M; Zandieh MA; Hushmandi K; Wang Y
Eur J Pharmacol; 2023 Sep; 955():175909. PubMed ID: 37490949
[TBL] [Abstract] [Full Text] [Related]
12. Dyskerin and telomerase RNA component are sex-differentially associated with outcomes and Sunitinib response in patients with clear cell renal cell carcinoma.
Yuan H; Qin X; Yang Q; Liu L; Fang Z; Fan Y; Xu D
Biol Sex Differ; 2023 Jul; 14(1):46. PubMed ID: 37434223
[TBL] [Abstract] [Full Text] [Related]
13. Macrophage-derived exosomal miR-342-3p promotes the progression of renal cell carcinoma through the NEDD4L/CEP55 axis.
Feng J; Xu B; Dai C; Wang Y; Xie G; Yang W; Zhang B; Li X; Wang J
Oncol Res; 2021; 29(5):331-349. PubMed ID: 37305161
[TBL] [Abstract] [Full Text] [Related]
14. [Precision oncology options in urological cancers].
Franz A; Plage H; Fendler A; Schlomm T; Kornienko K
Urologie; 2023 Jul; 62(7):696-704. PubMed ID: 37294331
[TBL] [Abstract] [Full Text] [Related]
15. BKM120 inhibits malignant rhabdoid tumor of the kidney through induction of apoptosis and G0/G1 phase arrest.
Liu J; Mi T; Zhang Z; Jin L; Li M; Zhanghuang C; Li M; Wang J; Wu X; Wang Z; Tan X; Wang Z; He D
Eur J Pharmacol; 2023 Jul; 951():175747. PubMed ID: 37142086
[TBL] [Abstract] [Full Text] [Related]
16. High-throughput and targeted drug screens identify pharmacological candidates against MiT-translocation renal cell carcinoma.
Lang M; Schmidt LS; Wilson KM; Ricketts CJ; Sourbier C; Vocke CD; Wei D; Crooks DR; Yang Y; Gibbs BK; Zhang X; Klumpp-Thomas C; Chen L; Guha R; Ferrer M; McKnight C; Itkin Z; Wangsa D; Wangsa D; James A; Difilippantonio S; Karim B; Morís F; Ried T; Merino MJ; Srinivasan R; Thomas CJ; Linehan WM
J Exp Clin Cancer Res; 2023 Apr; 42(1):99. PubMed ID: 37095531
[TBL] [Abstract] [Full Text] [Related]
17. Identification of circulating tumour DNA (ctDNA) from the liquid biopsy results: Findings from an observational cohort study.
Myint KZY; Shimabuku M; Horio R; Kaneda M; Shimizu Y; Taguchi J
Cancer Treat Res Commun; 2023; 35():100701. PubMed ID: 37094468
[TBL] [Abstract] [Full Text] [Related]
18. Identification of berberine as a potential therapeutic strategy for kidney clear cell carcinoma and COVID-19 based on analysis of large-scale datasets.
Zheng Z; Li X; Nie K; Wang X; Liang W; Yang F; Zheng K; Zheng Y
Front Immunol; 2023; 14():1038651. PubMed ID: 37033923
[TBL] [Abstract] [Full Text] [Related]
19. Combination treatment with FAAH inhibitors/URB597 and ferroptosis inducers significantly decreases the growth and metastasis of renal cell carcinoma cells via the pi3k-AKT signaling pathway.
Hao J; Chen Q; Feng Y; Jiang Q; Sun H; Deng B; Huang X; Guan J; Chen Q; Liu X; Wang Y; Cao P; Feng F; Li X
Cell Death Dis; 2023 Apr; 14(4):247. PubMed ID: 37024452
[TBL] [Abstract] [Full Text] [Related]
20. Identification of an immunogenic cell death-related gene signature predicts survival and sensitivity to immunotherapy in clear cell renal carcinoma.
Zhou S; Lu Y; Chen Y; Gan W
Sci Rep; 2023 Mar; 13(1):4449. PubMed ID: 36932108
[TBL] [Abstract] [Full Text] [Related]
[Next]
